<DOC>
	<DOCNO>NCT00150046</DOCNO>
	<brief_summary>This study test safety efficacy everolimus heart transplant recipient . This study recruit United States .</brief_summary>
	<brief_title>Efficacy Safety Everolimus de Novo Heart Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Male female cardiac recipient 1865 year age undergoing primary heart transplantation . The graft must functional time randomization . Calculated creatinine clearance ( CockroftGault ) ≥ 50 mL/min screening . Patients give write informed consent participate study . Patients recipients multiple solid organ transplant previously receive organ transplant . Patients receive investigational drug treat immunosuppressive drug treatment within 1 month prior randomization Patients receive induction therapy standard per local practice Patients donor great 60 year and/or know donor coronary heart disease time transplant . Donor heart cold ischemic time &gt; 6 hour . Patients Panel Reactive Antibodies &gt; 20 % . Patients recipient ABO incompatible transplant Patients platelet count &lt; 50,000/mm3 evaluation randomization . Presence severe hypercholesterolemia ( ≥350 mg/dL ; ≥9 mmol/L ) hypertriglyceridemia ( ≥750 mg/dL ; ≥8.5 mmol/L ) Patients absolute neutrophil count ≤1,500/mm3 white blood cell count ≤4000/mm3 baseline surgery Patients history significant coagulopathy medical condition require long term anticoagulation transplantation ( low dose aspirin treatment allow ) Patients HIVpositive Hepatitis C ( PCR+ ) B surface antigen positive . Laboratory result obtain within 6 month prior study entry acceptable . Recipients organs donor test positive Hepatitis B surface antigen Hepatitis C ( PCR+ ) exclude Patients know hypersensitivity similar drug component formulation Patients treated terfenadine , astemizole , cisapride . Patients treat drug strong inducer inhibitor cytochrome P450 3A4 . Patients past ( within past 5 year ) present malignancy ( excise basal cell carcinoma ) Patients clinically significant systemic infection Patients unable take oral medication Existence surgical medical condition , opinion investigator , might significantly alter absorption , distribution , metabolism excretion study medication , and/or presence severe diarrhea active peptic ulcer Abnormal physical laboratory finding clinical significance within 2 week randomization would interfere objective study Females childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Heart transplantation</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Heart transplant recipient</keyword>
</DOC>